Fintepla is a medicine used in addition to other epilepsy medicines to treat patients from 2 years of age who have Dravet syndrome or Lennox\-Gastaut syndrome, types of epilepsy that begin in childhood and continue into adulthood. These conditions are rare, and Fintepla was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the Agency’s website ([Dravet syndrome](/medicines/human/orphan-designations/eu3131219): 18 December 2013; [Lennox\-Gastaut syndrome](/medicines/human/orphan-designations/eu3171836): 27 February 2017\). Fintepla contains the active substance fenfluramine.
Therapeutic Indication
Treatment of seizures associated with Dravet syndrome as an add\-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox\-Gastaut syndrome as an add\-on therapy to other anti\-epileptic medicines for patients 2 years of age and older.
Therapeutic Area (MeSH)
ATC Code
N03
ATC Item
N/A
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
EMA Name
Fintepla
Medicine Name
Fintepla
Aliases
N/ANo risk management plan link.
